/ 13 April 2016

‘I’ve taken control of my life by taking the HIV prevention pill’

Ben Brown takes Truvada
Ben Brown takes Truvada

When Ben Brown (31) from Cape Town started to use an HIV prevention pill two years ago, it was because he wanted to “take charge” of his health.

“There’s this misunderstanding that we have this ultimate control over our sex life,” he says. “But really, there are so many factors outside our control that influence it and that sometimes result in us not using a condom. Or you use a condom and it breaks. I use this pill because I want that control back in my life.”

The pill Brown takes is a two-in-one antiretroviral drug called Truvada. Studies have shown that its two ingredients, tenofovir and emtricitabine, can prevent HIV infection in up to 90% of cases if the pill is taken daily at more or less the same time. Some demonstration projects have shown even higher protection rates.

“I take it every night along with my multivitamin tablet. It’s become a habit in my life; I don’t even think about it,” Brown says.

With more than 400 000 new HIV infections occurring in 2012, South Africa has the fastest-growing HIV epidemic in the world, according to the Human Sciences Research Council’s 2014 household survey.

The survey also found that more than half (52.9%) of the participants said they had never used condoms and that condom use had decreased from 85.2% among young men aged between 15 and 24 in 2008 to 67.5% in 2012.

“There are so many circumstances in people’s lives that sometimes prevent them from using condoms – whether they’re straight people, gay people, men or women,” Brown says. “Maybe you’re a lesbian that’s been sexually assaulted, maybe you’re a gay man who was taken advantage of, or maybe you’re a young woman who has an older man – who knows?”

Truvada must be taken more or less at the same time every day. (Delwyn Verasamy)

Pre-exposure prophylaxis
South Africa became the first African country, and the second in the world, to approve the use of Truvada as an HIV prevention pill in December. Using antiretroviral drugs as a form of HIV prevention is known as pre-exposure prophylaxis or PrEP. Antiretroviral medication is also used to treat HIV-infected people, but a combination of at least three different types of drugs is needed.

The United States Food and Drug Administration approved Truvada as PrEP in July 2012 and Kenya, the only other African country to have done so, approved it for use as HIV prevention about a month after South Africa did so.

Brown had to get tested for HIV over a period of two months before starting to use Truvada. During this period he had to ensure he wasn’t exposed to HIV and could therefore not have unprotected sex.

This is because there is a window period of between four and eight weeks in which the most common HIV test used in South Africa, known as an antibody test, might not detect the virus. The human body takes up to eight weeks to manufacture HIV antibodies.

“It was really important to ensure that I was HIV negative before taking PrEP. I still get tested once every three months, to monitor that I’m staying negative,” Brown says.

Brown’s doctor also assessed his risk of getting infected with HIV before prescribing Truvada. A month’s supply of the medication costs him about R500, but this could soon be cut in half when a generic version of the drug, which the Medicines Control Council approved this month, will become widely available.

The dos and don’ts of using an HIV prevention pill

[multimedia source=”http://bhekisisa.org/multimedia/2016-04-06-the-dos-and-donts-of-using-an-hiv-prevention-pill”]

No spike in risky behaviour
Research has shown that medication containing tenofovir and emtricitabine has very few side effects, although kidney dysfunction is a concern. But Brown has not experienced any. He says: “I’ve never had any side effects. Most importantly, it makes me feel confident and reassured that I don’t have to worry about becoming infected with HIV.”

Some in the public health sector are concerned that PrEP might lead to risky sexual behaviour, such as users increasing their number of sexual partners or having more sex without condoms.

But PrEP studies have shown that trial participants did not use condoms less than before they started with PrEP, because they were counselled on safer sex practices before taking the pill.

According to Kevin Rebe from the Anova Health Institute in Johannesburg, which is conducting a PrEP demonstration project in South Africa, doctors are expected to counsel their patients on the need for PrEP to be used in combination with other safer sex practices, such as promoting condom use for protection against sexually transmitted infections other than HIV, before prescribing the drug.

Brown says: “My behaviour certainly hasn’t changed since before I started taking PrEP. Whether or not I use condoms was always a decision I made with my partner. I think like everyone in the world, I can’t say I was always perfect using condoms. But it’s always been something I’ve done in partnership with the person I was seeing. And that hasn’t changed.”